-
DE
De Novo Lipogenesis: Fatty Acid Synthesis Explained
De novo lipogenesis is the metabolic process by which the body synthesizes fatty acids from non-fat precursors such as carbohydrates. It plays a key role in energy metabolism and metabolic disease.
Add as Preferred SourceThings worth knowing about "De novo lipogenesis"
De novo lipogenesis is the metabolic process by which the body synthesizes fatty acids from non-fat precursors such as carbohydrates. It plays a key role in energy metabolism and metabolic disease.
What Is De Novo Lipogenesis?
De novo lipogenesis (abbreviated DNL) refers to the biochemical synthesis of new fatty acids from non-lipid precursors – primarily carbohydrates, but also amino acids and other substrates. The term comes from Latin and literally means “new formation” (de novo) of fats (lipogenesis). It is a natural metabolic pathway found in virtually all mammals and occurs mainly in the liver and adipose (fat) tissue.
Biological Background and Occurrence
In humans, de novo lipogenesis takes place primarily in liver cells (hepatocytes). To a lesser extent, it also occurs in fat cells (adipocytes) and in the mammary gland during lactation. Under normal dietary conditions, DNL in humans is relatively low when energy intake is balanced. However, it increases significantly when carbohydrate or total caloric intake chronically exceeds energy expenditure.
Mechanism of De Novo Lipogenesis
The process proceeds through several biochemical steps:
- Glycolysis: Glucose is broken down into pyruvate.
- Acetyl-CoA formation: Pyruvate is converted to acetyl-CoA inside the mitochondria.
- Citrate transport: Acetyl-CoA enters the citric acid cycle and is converted to citrate, which is then exported from the mitochondria into the cytoplasm.
- Malonyl-CoA synthesis: The enzyme acetyl-CoA carboxylase (ACC) converts acetyl-CoA to malonyl-CoA – the first and rate-limiting step of fatty acid synthesis.
- Fatty acid synthesis: The fatty acid synthase complex (FAS/FASN) elongates the carbon chain stepwise until palmitate (C16:0) is produced – the primary end product of DNL.
- Further processing: Palmitate can subsequently be elongated or desaturated into longer-chain or unsaturated fatty acids.
Regulation of De Novo Lipogenesis
DNL is regulated by a variety of hormonal and nutrient-dependent signaling pathways:
- Insulin: Promotes DNL by activating the transcription factor SREBP-1c (sterol regulatory element-binding protein 1c), which upregulates genes involved in fatty acid synthesis.
- Glucose and fructose: High concentrations of these sugars stimulate DNL directly. Fructose is considered a particularly potent activator because it rapidly replenishes the acetyl-CoA pool.
- AMPK (AMP-activated protein kinase): Inhibits DNL during low-energy states by inactivating acetyl-CoA carboxylase.
- Glucagon and catecholamines: Inhibit DNL via activation of AMPK and suppression of SREBP-1c.
De Novo Lipogenesis and Nutrition
The type and quantity of nutrients consumed significantly affects DNL activity:
- High-carbohydrate diets: Consistently high carbohydrate intake, especially from simple sugars like sucrose and fructose, strongly activates DNL.
- Caloric surplus: Any energy intake exceeding expenditure – regardless of macronutrient source – promotes de novo fatty acid synthesis.
- Low-carbohydrate or ketogenic diets: Markedly reduce DNL by limiting the availability of acetyl-CoA for lipogenesis.
Clinical Significance
Chronically elevated de novo lipogenesis is associated with several metabolic disorders:
- Non-alcoholic fatty liver disease (NAFLD/MASLD): In individuals with obesity and insulin resistance, hepatic DNL is substantially increased and contributes significantly to liver fat accumulation.
- Metabolic syndrome: Elevated DNL activity correlates with hypertriglyceridemia, visceral obesity, and insulin resistance.
- Type 2 diabetes mellitus: Increased hepatic fat export raises VLDL-triglyceride levels in the blood and worsens insulin sensitivity.
- Obesity: Chronic caloric surplus stimulates DNL and contributes to increases in fat mass over time.
Therapeutic Approaches
Given the clinical relevance of de novo lipogenesis, several strategies are being investigated to modulate its activity:
- Dietary interventions: Reducing fructose, sucrose, and overall caloric intake to lower hepatic DNL.
- Pharmacological inhibitors: Agents such as ACC inhibitors (e.g., firsocostat) are being evaluated in clinical trials for NAFLD.
- FASN inhibitors: Inhibitors of fatty acid synthase are under investigation in both metabolic medicine and oncology, as many tumor cells exhibit elevated DNL.
- Exercise and physical activity: Activates AMPK and thereby suppresses DNL.
De Novo Lipogenesis in Oncology
An emerging area of research concerns the role of de novo lipogenesis in cancer cells. Many tumor cells show markedly elevated FASN expression and increased lipogenic activity. This is interpreted as an adaptation to the high biosynthetic demands of rapidly dividing cells, closely related to the concept of the Warburg effect. Accordingly, FASN inhibitors are being explored as potential anticancer agents.
References
- Strable, M. S. & Ntambi, J. M. (2010): Genetic control of de novo lipogenesis: Role in diet-induced obesity. Critical Reviews in Biochemistry and Molecular Biology, 45(3), 199–214. DOI: 10.3109/10409231003667500
- Loomba, R. et al. (2021): De novo lipogenesis as a key driver of nonalcoholic fatty liver disease. Journal of Hepatology, 76(3), 700–710. DOI: 10.1016/j.jhep.2021.07.005
- Hanahan, D. & Weinberg, R. A. (2011): Hallmarks of Cancer: The Next Generation. Cell, 144(5), 646–674. DOI: 10.1016/j.cell.2011.02.013
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Skip product gallery
Subscription available
Floral
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®30 lozenges
Regular price:
€22.90
Discount
Subscription available
Lactoferrin 60 Capsules
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
60 Capsules
Sale price:
€50.00
Regular price:
€59.90
Discount
Subscription available
Multivitamin Mineral Complex
Daily basic supply: the complete spectrum of micronutrients
Natural multivitamin complex for the immune system, energy, and central body functions
30 Capsules
Sale price:
€27.90
Regular price:
€29.90
Subscription available
Natural Iron
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
30 Capsules
Regular price:
€35.90
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Magnesiumcarbonat ist eine anorganische Magnesiumverbindung mit säure-neutralisierender (antazidischer) Wirkung. Erfahre mehr über Vorteile, Einsatzgebiete und Unterschiede zu besser resorbierbaren Magnesiumformen.
Calorie content
The choice of food influences our energy intake. The calorie content varies greatly - some provide little energy, others a lot.
Cologne list
The Cologne List ® is an important initiative in competitive sports that offers athletes guidance in the selection of nutritional supplements.